Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.

about

GBM skin metastasis: a case report and review of the literature.JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.

P2860

Q39441170-5DE78C12-970A-4EF8-BF91-C481800FE7EA Q54252845-199B59FA-0B81-459C-AE14-7FC8E22EFDBE

P2860

Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.

Item

http://www.wikidata.org/entity/Q41562532

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Interferon-β and temozolomide ...... -refractory malignant gliomas.

@en

type

Item

label

Interferon-β and temozolomide ...... -refractory malignant gliomas.

@en

prefLabel

Interferon-β and temozolomide ...... -refractory malignant gliomas.

@en

P1476

Interferon-β and temozolomide ...... -refractory malignant gliomas.

@en

P2093

Hiroki Namba

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kawaji

http://www.w3.org/2001/XMLSchema#string

Naoto Sakai

http://www.w3.org/2001/XMLSchema#string

Shinji Amano

http://www.w3.org/2001/XMLSchema#string

Tomohiro Yamasaki

http://www.w3.org/2001/XMLSchema#string

Tsutomu Tokuyama

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Current trends in targeted therapies for glioblastoma multiforme

Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.

Glioblastoma and other malignant gliomas: a clinical review.

Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.

Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.

A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.

Potentiation of antiglioma effect with combined temozolomide and interferon-beta.

IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.

Two different mechanisms of apoptosis resistance observed in interferon-beta induced apoptosis of human glioma cells.

P304

909-913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2015.542

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275242005

http://www.w3.org/2001/XMLSchema#string

P698

26171205

http://www.w3.org/2001/XMLSchema#string

P932

4486788

http://www.w3.org/2001/XMLSchema#string

Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.

about

P2860

P2860

Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932